Medical - Diagnostics & Research
Compare Stocks
4 / 10Stock Comparison
DHR vs A vs TMO vs WAT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
DHR vs A vs TMO vs WAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $123.80B | $33.31B | $175.76B | $22.78B |
| Revenue (TTM) | $24.78B | $7.07B | $45.20B | $3.77B |
| Net Income (TTM) | $3.69B | $1.29B | $6.86B | $449M |
| Gross Margin | 60.7% | 38.8% | 39.4% | 55.0% |
| Operating Margin | 21.0% | 20.6% | 17.8% | 17.1% |
| Forward P/E | 20.7x | 19.7x | 19.0x | 24.3x |
| Total Debt | $18.42B | $3.35B | $40.85B | $1.41B |
| Cash & Equiv. | $4.62B | $1.79B | $9.86B | $588M |
DHR vs A vs TMO vs WAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Danaher Corporation (DHR) | 100 | 118.4 | +18.4% |
| Agilent Technologie… (A) | 100 | 133.5 | +33.5% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
| Waters Corporation (WAT) | 100 | 174.9 | +74.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DHR vs A vs TMO vs WAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DHR is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.
- Lower volatility, beta 0.94, Low D/E 35.1%, current ratio 1.87x
- Beta 0.94 vs A's 1.23, lower leverage
A carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 10 yrs, beta 1.23, yield 0.8%
- PEG 1.34 vs DHR's 34.20
- Beta 1.23, yield 0.8%, current ratio 1.96x
- Lower P/E (19.7x vs 24.3x), PEG 1.34 vs 4.69
TMO is the clearest fit if your priority is long-term compounding.
- 229.1% 10Y total return vs DHR's 218.0%
- +16.6% vs DHR's -7.2%
WAT is the clearest fit if your priority is growth exposure.
- Rev growth 7.0%, EPS growth 0.5%, 3Y rev CAGR 2.1%
- 7.0% revenue growth vs DHR's 2.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs DHR's 2.9% | |
| Value | Lower P/E (19.7x vs 24.3x), PEG 1.34 vs 4.69 | |
| Quality / Margins | 18.3% margin vs WAT's 11.9% | |
| Stability / Safety | Beta 0.94 vs A's 1.23, lower leverage | |
| Dividends | 0.8% yield, 10-year raise streak, vs TMO's 0.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +16.6% vs DHR's -7.2% | |
| Efficiency (ROA) | 10.1% ROA vs DHR's 4.5%, ROIC 13.5% vs 5.9% |
DHR vs A vs TMO vs WAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DHR vs A vs TMO vs WAT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DHR leads in 2 of 6 categories
WAT leads 2 • A leads 1 • TMO leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DHR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 12.0x WAT's $3.8B. A is the more profitable business, keeping 18.3% of every revenue dollar as net income compared to WAT's 11.9%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $24.8B | $7.1B | $45.2B | $3.8B |
| EBITDAEarnings before interest/tax | $7.2B | $1.7B | $10.5B | $953M |
| Net IncomeAfter-tax profit | $3.7B | $1.3B | $6.9B | $449M |
| Free Cash FlowCash after capex | $5.3B | $993M | $6.7B | $264M |
| Gross MarginGross profit ÷ Revenue | +60.7% | +38.8% | +39.4% | +55.0% |
| Operating MarginEBIT ÷ Revenue | +21.0% | +20.6% | +17.8% | +17.1% |
| Net MarginNet income ÷ Revenue | +14.9% | +18.3% | +15.2% | +11.9% |
| FCF MarginFCF ÷ Revenue | +21.4% | +14.1% | +14.9% | +7.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.7% | +7.0% | +6.2% | +91.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.8% | -3.6% | +11.3% | -142.9% |
Valuation Metrics
DHR leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 25.8x trailing earnings, A trades at a 26% valuation discount to DHR's 34.7x P/E. Adjusting for growth (PEG ratio), A offers better value at 1.75x vs DHR's 34.20x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $123.8B | $33.3B | $175.8B | $22.8B |
| Enterprise ValueMkt cap + debt − cash | $137.6B | $34.9B | $206.8B | $23.6B |
| Trailing P/EPrice ÷ TTM EPS | 34.71x | 25.75x | 26.66x | 32.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.73x | 19.71x | 19.04x | 24.30x |
| PEG RatioP/E ÷ EPS growth rate | 34.20x | 1.75x | 12.62x | 6.27x |
| EV / EBITDAEnterprise value multiple | 18.14x | 19.74x | 18.99x | 21.47x |
| Price / SalesMarket cap ÷ Revenue | 5.04x | 4.79x | 3.94x | 7.20x |
| Price / BookPrice ÷ Book value/share | 2.37x | 4.96x | 3.33x | 8.15x |
| Price / FCFMarket cap ÷ FCF | 23.54x | 28.92x | 27.93x | 42.21x |
Profitability & Efficiency
WAT leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
A delivers a 18.7% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $7 for DHR. DHR carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs WAT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.1% | +18.7% | +13.2% | +8.0% |
| ROA (TTM)Return on assets | +4.5% | +10.1% | +6.4% | +4.6% |
| ROICReturn on invested capital | +5.9% | +13.5% | +7.5% | +20.3% |
| ROCEReturn on capital employed | +7.0% | +14.5% | +9.1% | +18.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.35x | 0.50x | 0.76x | 0.55x |
| Net DebtTotal debt minus cash | $13.8B | $1.6B | $31.0B | $820M |
| Cash & Equiv.Liquid assets | $4.6B | $1.8B | $9.9B | $588M |
| Total DebtShort + long-term debt | $18.4B | $3.4B | $40.9B | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | 18.13x | 19.53x | 5.89x | 6.72x |
Total Returns (Dividends Reinvested)
WAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WAT five years ago would be worth $11,311 today (with dividends reinvested), compared to $7,907 for DHR. Over the past 12 months, TMO leads with a +16.6% total return vs DHR's -7.2%. The 3-year compound annual growth rate (CAGR) favors WAT at 5.6% vs DHR's -5.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -23.9% | -14.3% | -20.1% | -8.5% |
| 1-Year ReturnPast 12 months | -7.2% | +12.8% | +16.6% | +3.1% |
| 3-Year ReturnCumulative with dividends | -15.9% | -9.0% | -11.9% | +17.9% |
| 5-Year ReturnCumulative with dividends | -20.9% | -7.7% | +2.1% | +13.1% |
| 10-Year ReturnCumulative with dividends | +218.0% | +202.6% | +229.1% | +163.2% |
| CAGR (3Y)Annualised 3-year return | -5.6% | -3.1% | -4.2% | +5.6% |
Risk & Volatility
Evenly matched — DHR and WAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DHR is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than A's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WAT currently trades 84.4% from its 52-week high vs DHR's 72.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 1.23x | 1.10x | 1.07x |
| 52-Week HighHighest price in past year | $242.80 | $160.27 | $643.99 | $414.15 |
| 52-Week LowLowest price in past year | $172.06 | $104.36 | $385.46 | $275.05 |
| % of 52W HighCurrent price vs 52-week peak | +72.0% | +73.4% | +73.4% | +84.4% |
| RSI (14)Momentum oscillator 0–100 | 32.3 | 52.2 | 39.8 | 62.7 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 2.0M | 1.9M | 989K |
Analyst Outlook
A leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DHR as "Buy", A as "Buy", TMO as "Buy", WAT as "Hold". Consensus price targets imply 41.2% upside for DHR (target: $247) vs 15.2% for WAT (target: $403). For income investors, A offers the higher dividend yield at 0.84% vs TMO's 0.36%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $247.00 | $166.00 | $654.67 | $402.57 |
| # AnalystsCovering analysts | 42 | 38 | 42 | 34 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | +0.8% | +0.4% | — |
| Dividend StreakConsecutive years of raises | 1 | 10 | 8 | 1 |
| Dividend / ShareAnnual DPS | $1.23 | $0.99 | $1.69 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.5% | +1.3% | +1.7% | +0.1% |
DHR leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). WAT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
DHR vs A vs TMO vs WAT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DHR or A or TMO or WAT a better buy right now?
For growth investors, Waters Corporation (WAT) is the stronger pick with 7.
0% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Agilent Technologies, Inc. (A) offers the better valuation at 25. 8x trailing P/E (19. 7x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DHR or A or TMO or WAT?
On trailing P/E, Agilent Technologies, Inc.
(A) is the cheapest at 25. 8x versus Danaher Corporation at 34. 7x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Agilent Technologies, Inc. wins at 1. 34x versus Danaher Corporation's 34. 20x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — DHR or A or TMO or WAT?
Over the past 5 years, Waters Corporation (WAT) delivered a total return of +13.
1%, compared to -20. 9% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: TMO returned +229. 1% versus WAT's +163. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DHR or A or TMO or WAT?
By beta (market sensitivity over 5 years), Danaher Corporation (DHR) is the lower-risk stock at 0.
94β versus Agilent Technologies, Inc. 's 1. 23β — meaning A is approximately 31% more volatile than DHR relative to the S&P 500. On balance sheet safety, Danaher Corporation (DHR) carries a lower debt/equity ratio of 35% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DHR or A or TMO or WAT?
By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.
0% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Thermo Fisher Scientific Inc. grew EPS 7. 3% year-over-year, compared to -4. 7% for Danaher Corporation. Over a 3-year CAGR, WAT leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DHR or A or TMO or WAT?
Waters Corporation (WAT) is the more profitable company, earning 20.
3% net margin versus 14. 7% for Danaher Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 18. 2% for TMO. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DHR or A or TMO or WAT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Agilent Technologies, Inc. (A) is the more undervalued stock at a PEG of 1. 34x versus Danaher Corporation's 34. 20x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 0x forward P/E versus 24. 3x for Waters Corporation — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 41. 2% to $247. 00.
08Which pays a better dividend — DHR or A or TMO or WAT?
In this comparison, A (0.
8% yield), DHR (0. 7% yield), TMO (0. 4% yield) pay a dividend. WAT does not pay a meaningful dividend and should not be held primarily for income.
09Is DHR or A or TMO or WAT better for a retirement portfolio?
For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
94), 0. 7% yield, +218. 0% 10Y return). Both have compounded well over 10 years (DHR: +218. 0%, WAT: +163. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DHR and A and TMO and WAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
DHR, A pay a dividend while TMO, WAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.